GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cardio Diagnostics Holdings Inc (NAS:CDIO) » Definitions » Cash Ratio

CDIO (Cardio Diagnostics Holdings) Cash Ratio : 12.38 (As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Cardio Diagnostics Holdings Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Cardio Diagnostics Holdings's Cash Ratio for the quarter that ended in Dec. 2024 was 12.38.

Cardio Diagnostics Holdings has a Cash Ratio of 12.38. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.

The historical rank and industry rank for Cardio Diagnostics Holdings's Cash Ratio or its related term are showing as below:

CDIO' s Cash Ratio Range Over the Past 10 Years
Min: 0.61   Med: 2.11   Max: 15.09
Current: 12.38

During the past 5 years, Cardio Diagnostics Holdings's highest Cash Ratio was 15.09. The lowest was 0.61. And the median was 2.11.

CDIO's Cash Ratio is ranked better than
86.51% of 1468 companies
in the Biotechnology industry
Industry Median: 2.71 vs CDIO: 12.38

Cardio Diagnostics Holdings Cash Ratio Historical Data

The historical data trend for Cardio Diagnostics Holdings's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cardio Diagnostics Holdings Cash Ratio Chart

Cardio Diagnostics Holdings Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Cash Ratio
0.61 15.09 2.11 1.53 12.38

Cardio Diagnostics Holdings Quarterly Data
Dec20 Mar21 Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cash Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.53 2.28 3.48 6.42 12.38

Competitive Comparison of Cardio Diagnostics Holdings's Cash Ratio

For the Biotechnology subindustry, Cardio Diagnostics Holdings's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cardio Diagnostics Holdings's Cash Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cardio Diagnostics Holdings's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Cardio Diagnostics Holdings's Cash Ratio falls into.


;
;

Cardio Diagnostics Holdings Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Cardio Diagnostics Holdings's Cash Ratio for the fiscal year that ended in Dec. 2024 is calculated as:

Cash Ratio (A: Dec. 2024 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=7.827/0.632
=12.38

Cardio Diagnostics Holdings's Cash Ratio for the quarter that ended in Dec. 2024 is calculated as:

Cash Ratio (Q: Dec. 2024 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=7.827/0.632
=12.38

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cardio Diagnostics Holdings  (NAS:CDIO) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


Cardio Diagnostics Holdings Cash Ratio Related Terms

Thank you for viewing the detailed overview of Cardio Diagnostics Holdings's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Cardio Diagnostics Holdings Business Description

Traded in Other Exchanges
N/A
Address
311 West Superior Street, Suite 444, Chicago, IL, USA, 60654
Cardio Diagnostics Holdings Inc is a biotechnology company that makes cardiovascular disease prevention and early detection more accessible, personalized, and precise. The company was formed to further develop and commercialize a proprietary artificial intelligence-driven integrated Genetic-Epigenetic EngineTM for cardiovascular disease to become the leading medical technology company for enabling improved prevention, early detection, and assistance in the treatment of cardiovascular disease.
Executives
Robert Philibert director, 10 percent owner, officer: Chief Medical Officer 400 N. ABERDEEN, SUITE 900, CHICAGO IL 60642
Timur Dogan officer: Chief Technology Officer 400 N. ABERDEEN ST., SUITE 900, CHICAGO IL 60642
Meeshanthini Dogan director, 10 percent owner, officer: Chief Executive Officer 400 N. ABERDEEN ST., SUITE 900, CHICAGO IL 60642
Warren Hosseinion director C/O 1668 S. GARFIELD AVENUE, 2ND FLOOR, ALHAMBRA CA 91801
Elisa V Luqman officer: Chief Financial Officer 37 HARRISON DRIVE, NORTHPORT NY 11768
Khullani Abdullahi officer: VP of Revenue and Strategy 400 N. ABERDEEN ST., SUITE 900, CHICAGO IL 60642
Brandon Sim director C/O APOLLO MEDICAL HOLDINGS, INC., 1668 S. GARFIELD AVENUE, 3RD FLOOR, ALHAMBRA CA 91801
James Intrater director C/O CARDIO DIAGNOSTICS HOLDINGS INC., 400 N. ABERDEEN ST., SUITE 900, CHICAGO IL 60642
Oded Levy director C/O CARDIO DIAGNOSTICS HOLDINGS INC., 400 N. ABERDEEN ST., SUITE 900, CHICAGO IL 60642
Stanley K. Lau director C/O CARDIO DIAGNOSTICS HOLDINGS INC., 400 N. ABERDEEN ST., SUITE 900, CHICAGO IL 60642
Bd Holding, Inc. 10 percent owner 15 PROSPECT PLACE, IOWA CITY IA 52246
Jonathan Intrater officer: CEO 223 PALMER STREET, PALMER MA 01069
Allan Liu director 1600 PARKWOOD CIRCLE, STE 200, ATLANTA GA 30339-2119
Loren Mortman director 207 EAST 74TH STREET, APARTMENT 10F, NEW YORK NY 10021
Mana Capital Llc 10 percent owner 8 THE GREEN, SUITE A, DOVER DE 19901

Cardio Diagnostics Holdings Headlines

From GuruFocus